The Lilly MDR-TB Partnership

AN OVERVIEW

Partnerships to better address TB/MDR-TB control

Geneva
14 April 2010

Patrizia Carlevaro
Head, International Aid Unit
Eli Lilly and Company
Where it all began

- **1992** - Partners in Health (PIH) staff dies of MDR-TB on his return to the USA. TB was resistant to at least isoniazid (H) and rifampicin (R). Study of treatment failures revealed 16% prevalence of MDR-TB in Peru.

- **1996** - Treatment started in cooperation with the National Tuberculosis Program (NTP) at Massachusetts State Laboratory (USA).

- **2000** - Lilly provided MSF and WHO with 2 anti-TB drugs at concessionary prices, and the Green Light Committee (GLC) was created.

- **2003** - Launch of MDR-TB Partnership to support and provide medicines for pilot initiatives in resource-constrained countries worldwide.
Global MDR-TB Challenge for Businesses & Communities

- MDR-TB prolonged and complex treatment can result in poor patient compliance and development of drug resistance

- Decline in worker productivity to the order of US$13 billion annually*

  Lilly has organized health professionals, businesses, academic institutions, and communities in a comprehensive US$135 million MDR-TB program

Since 2003, Lilly has lead a comprehensive approach to fighting MDR-TB through:

- **Community Support and Patient Advocacy**
- **Awareness and Prevention**
- **Treatment, Training and Surveillance**
- **Transferring Technology**
- **Research**
- Reaching patients throughout the world

**MISSION:** to combat the growing MDR-TB pandemic and to support the Global Plan to Stop TB.
The Global Partners

- Akorn, U.S.
- Aspen Pharmacare, South Africa
- Cause Première
- Eli Lilly and Company
- Global Business Coalition (GBC)
- Global Health Advocates (GHA)
- Harvard Medical School and Partners in Health (PIH)
- Hisun Pharmaceutical, China
- International Council of Nurses (ICN)
- International Fed. of Red Cross and Red Crescent Societies (IFRC)
- International Hospital Federation (IHF)
- Purdue University, USA
- RESULTS Educational Fund
- Shasun Chemicals and Drugs, India
- SIA International/Biocom, Russia
- Stop TB Partnership
- TB Alert
- The Advocacy Partnership
- U.S. Centers for Disease Control and Prevention (CDC)
- Vianex S.A.
- World Economic Forum (WEF)
- World Health Organization (WHO)
- World Medical Association (WMA)

Reaching patients throughout the world
360 degree approach

Healthcare Professional Education Program

International Council of Nurses (ICN)
Scope/reach: more than 13 million nurses worldwide
- Training of Trainers. Conduct in-country training with local nurses associations
- Development of framework and advocacy for TB and MDR-TB curriculum in nursing schools

World Medical Association (WMA)
Scope/reach: 7 million physicians worldwide
- Development distance learning course for physicians addressing the clinical aspects of MDR-TB, and TB Refresher course
- Conduct in-country training with local medical associations

International Hospital Federation (IHF)
Scope/reach: 60,000 hospital facilities worldwide
- Production of MDR-TB control manuals and disseminated to public and private hospitals and clinics
- Joint infection control activities
Community Support and Patient Advocacy

International Federation of Red Cross and Red Crescent
- Community support to people living with MDR-TB ensuring better access to care and improved compliance

Country Support and Technical Assistance

World Health Organization
- Technical assistance to MDR-TB control projects globally
- Training for MDR-TB project implementation
- Drug resistance surveillance and laboratory strengthening

Awareness and Prevention

TB Survival Project
- Patient-led initiative to raise awareness and engage patients and their families worldwide

Stop TB Partnership
- Advocacy and awareness campaign involving football star Luis Figo as goodwill ambassador
- Journalism and Photo journalism Awards
360 degree approach

TB and MDR-TB in the workplace

Partnership with the World Economic Forum (WEF)
- Develop a Global Awareness Toolkit for Tuberculosis/MDR-TB in the Workplace and disseminate through WEF member companies (China, India, South Africa)
- Provide educational material targeting employees and in-plant healthcare staff

Advocacy and awareness in the workplace

Partnership with the Global Business Coalition (GBC)
- Disseminated 400,000 card decks with TB awareness/advocacy messages in Beijing train stations (target: migrant workers)
- Workplace TB/HIV trainings in South Africa
- Development of a TB Policy website in Russian
Activities in Over 80 Countries
Transfer of Technology

- Share Lilly’s specific and general manufacturing knowledge
- Create self-sustaining centers of manufacturing excellence capable of providing additional products and employment
- Support reliable generic producers to ensure expanded multi-source availability of the two drugs
- Offer manufacturing firms in MDR-TB “hot spots” (China, India, Russia, South Africa) the technology to produce two second-line TB drugs
- Training in Good Manufacturing and Good Business Practices with support from Purdue University (USA)
- Provide Lilly staff on-site for technical assistance/training
The Lilly TB Drug Discovery Initiative is a public-private partnership to fill the early-stage pipeline for future drug development.

The Initiative’s primary members are Eli Lilly and Company, the Infectious Disease Research Institute, and the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health.

The Initiative has unique access to proprietary chemical libraries, and is accelerating the identification of new clinical candidates by bringing together global specialists for the systematic exploration of vast, private molecular libraries.
Lilly MDR-TB Partnership
360 degree approach:
The India Example

Community Support by TB Alert

Media workshops

Transfer of Technology to Shasun

Local activities in India

- Partnership with TB Alert India, Delhi
- Partnership with CARE INDIA and Children’s International, West Bengal
- Partnership in Hyderabad TB Alert
- Radio campaign in Kerala on World TB Day
- Radio Campaign in Mumbai on World TB Day
- Support of Govt. Of India, Pilot MDR TB Initiative in Ahmedabad, Gujarat
- Media campaign, Delhi and National Capital Region
- Patients support program for DOTS PLUS, Delhi
- Toy donation drive
- Indian Medical Association training of PPs in Himachal Pradesh

Indian Medical Association partnership for public-private mix, Madhya Pradesh
Empowering the Teen community in India

Teen Campaign to Reduce TB Cases in India launched on World Youth Day - Partnership with Children International

• Under the program, 15-20 motivated trained teens trained to become ‘Youth Peer Educators’ who will then use a variety of health education techniques to educate the community of two neighborhoods of Kolkata.

Little K. Manisha doing her homework after school. She particularly enjoys books with lots of pictures.

Photo part of Lilly MDR-TB Partnership Photo Exhibit ‘Faces of TB’. Photo credits: Subhash Sharma
Some Key Achievements

More than 1,000 physicians and over 300 hospital managers trained.

Over 1,900 MDR-TB patients receive direct supervision from the Red Cross

1,500 companies received workplace toolkit

Over 300 journalists trained.

Dissemination of tools to 65,000 hospitals in some 100 countries, covering 300,000 Healthcare professionals.

Stop TB Campaign with Luis Figo adapted in 11 languages

19,000 nurses have been trained

WHO has approved over 60,000 patients for treatment globally
Contact Information

Patrizia Carlevaro
Head, International Aid Unit
Eli Lilly and Company
Geneva, Switzerland
carlevaro_patrizia@lilly.com
www.lillymdr-tb.com